Myeloid-derived suppressor cells - their role in haemato-oncological malignancies and other cancers and possible implications for therapy

British Journal of Haematology

Volumn 153, Issue 5, 2011, Pages 557-567

  Tadmor, Tamar ^a   Attias, Dina ^a   Polliack, Aaron ^b  

^a BNAI ZION MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY   (Israel)

Author keywords

Granulocytic MDSCs; Monocytic MDSCs; Myeloid derived suppressor cells

Indexed keywords

ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ARGININE; BEVACIZUMAB; CELECOXIB; CYCLOPHOSPHAMIDE; CYSTEINE; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; INTERLEUKIN 12; INTERLEUKIN 2; L SELECTIN; RETINOIC ACID; SILDENAFIL; STAT3 PROTEIN; SUNITINIB; TRITERPENOID; VITAMIN D DERIVATIVE;

AMINO ACID TRANSPORT; BONE MARROW CELL; BREAST CANCER; CANCER THERAPY; CELL DIFFERENTIATION; CELL HETEROGENEITY; DOWN REGULATION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE RESPONSE; KIDNEY CARCINOMA; MESOTHELIOMA; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; T LYMPHOCYTE; TUMOR VASCULARIZATION;

ANTINEOPLASTIC AGENTS; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNE TOLERANCE; IMMUNOPHENOTYPING; MALE; MYELOID CELLS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 79955740671     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08678.x     Document Type: Review

References (70)

1. Abe, F., Dafferner, A.J., Donkor, M., Westphal, S.N., Scholar, E.M., Solheim, J.C., Singh, R.K., Hoke, T.A. & Talmadge, J.E. (2010) Myeloid-derived suppressor cells in mammary tumor progression in FVB Neu transgenic mice. Cancer Immunology Immunotherapy, 59, 47-62.
2. Angulo, I., de las Heras, F.G., Garcia-Bustos, J.F., Gargallo, D., Munoz-Fernandez, M.A. & Fresno, M. (2000) Nitric oxide-producing CD11b+Ly-6G(Gr-1)+CD31(ER-MP12)+ cells in the spleen of cyclophosphamide-treated mice: implications for T-cell responses in immunosuppressed mice. Blood, 95, 212-220.
3. Brandau, S., Trellakis, S., Bruderek, K., Schmaltz, D., Steller, G., Elian, M., Suttmann, H., Schenck, M., Welling, J., Zabel, P. & Lang, S. (2011) Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties. Journal of Leukocyte Biology, 89, 311-317.
4. Bronte, V. (2009) Myeloid-derived suppressor cells in inflammation: uncovering cell subsets with enhanced immunosuppressive functions. European Journal of Immunology, 39, 2670-2672.
5. Bunt, S.K., Sinha, P., Clements, V.K., Leips, J. & Ostrand-Rosenberg, S. (2006) Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. Journal of Immunology, 176, 284-290.
6. Bunt, S.K., Yang, L., Sinha, P., Clements, V.K., Leips, J. & Ostrand-Rosenberg, S. (2007) Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Research, 67, 10019-10026.
7. Chornoguz, O., Grmai, L., Sinha, P., Artemenko, K., Zubarev, R. & Ostrand-Rosenberg, S. (2011) Proteomic pathway analysis reveals inflammation increases myeloid-derived suppressor cell resistance to apoptosis. Molecular and Cellular Proteomics, 10, M110.002980.
8. De Santo, C., Serafini, P., Marigo, I., Dolcetti, L., Bolla, M., Del Soldato, P., Melani, C., Guiducci, C., Colombo, M.P., Iezzi, M., Musiani, P., Zanovello, P. & Bronte, V. (2005) Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proceeding of the National Academy of Sciences of the USA, 102, 4185-4190.
9. Diaz-Montero, C.M., Salem, M.L., Nishimura, M.I., Garrett-Mayer, E., Cole, D.J. & Montero, A.J. (2009) Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunology Immunotherapy, 58, 49-59.
10. Dugast, A.S., Haudebourg, T., Coulon, F., Heslan, M., Haspot, F., Poirier, N., Vuillefroy de Silly, R., Usal, C., Smit, H., Martinet, B., Thebault, P., Renaudin, K. & Vanhove, B. (2008) Myeloid-derived suppressor cells accumulate in kidney allograft tolerance and specifically suppress effector T cell expansion. The Journal of Immunology, 180, 7898-7906.
11. Filipazzi, P., Valenti, R., Huber, V., Pilla, L., Canese, P., Iero, M., Castelli, C., Mariani, L., Parmiani, G. & Rivoltini, L. (2007) Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. Journal of Clinical Oncology, 25, 2546-2553.
12. Gabrilovich, D.I. & Nagaraj, S. (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nature Reviews Immunology, 9, 162-174.
13. Gabrilovich, D., Ishida, T., Oyama, T., Ran, S., Kravtsov, V., Nadaf, S. & Carbone, D.P. (1998) Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood, 92, 4150-4166.
14. Gabrilovich, D.I., Velders, M.P., Sotomayor, E.M. & Kast, W.M. (2001) Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. The Journal of Immunology, 166, 5398-5406.
15. Gabrilovich, D.I., Bronte, V., Chen, S.H., Colombo, M.P., Ochoa, A., Ostrand-Rosenberg, S. & Schreiber, H. (2007) The terminology issue for myeloid-derived suppressor cells. Cancer Research, 67, 425; author reply 426.
16. Greten, T.F., Manns, M.P. & Korangy, F. (2011) Myeloid derived suppressor cells in human diseases. International Immunopharmacology. Epub ahead of print, doi.
17. Haile, L.A., von Wasielewski, R., Gamrekelashvili, J., Kruger, C., Bachmann, O., Westendorf, A.M., Buer, J., Liblau, R., Manns, M.P., Korangy, F. & Greten, T.F. (2008) Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway. Gastroenterology, 135, 871-881.
18. Hoechst, B., Ormandy, L.A., Ballmaier, M., Lehner, F., Kruger, C., Manns, M.P., Greten, T.F. & Korangy, F. (2008) A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology, 135, 234-243.
19. Hoechst, B., Voigtlaender, T., Ormandy, L., Gamrekelashvili, J., Zhao, F., Wedemeyer, H., Lehner, F., Manns, M.P., Greten, T.F. & Korangy, F. (2009) Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology, 50, 799-807.
20. Huang, B., Pan, P.Y., Li, Q., Sato, A.I., Levy, D.E., Bromberg, J., Divino, C.M. & Chen, S.H. (2006) Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Research, 66, 1123-1131.
21. Ilkovitch, D. & Lopez, D.M. (2009a) The liver is a site for tumor-induced myeloid-derived suppressor cell accumulation and immunosuppression. Cancer Research, 69, 5514-5521.
22. Ilkovitch, D. & Lopez, D.M. (2009b) Urokinase-mediated recruitment of myeloid-derived suppressor cells and their suppressive mechanisms are blocked by MUC1/sec. Blood, 113, 4729-4739.
23. Kirberg, J., Berns, A. & Boehmer, H.V (1997) Peripheral T cell survival requires continual ligation of the T cell receptor to major histocompatibility complex-encoded molecules. The Journal of Experimental Medicine, 186, 1269-1275.
24. Ko, J.S., Zea, A.H., Rini, B.I., Ireland, J.L., Elson, P., Cohen, P., Golshayan, A., Rayman, P.A., Wood, L., Garcia, J., Dreicer, R., Bukowski, R. & Finke, J.H. (2009a) Sunitinib mediates reversal of myeloid derived suppressor cell accumulation in renal cell carcinoma patients. Clinical Cancer Research, 15, 2148-2157.
25. Ko, J.S., Bukowski, R.M. & Fincke, J.H. (2009b) Myeloid-derived suppressor cells: a novel therapeutic target. Current Oncology Reports, 11, 87-93.
26. Kusmartsev, S., Su, Z., Heiser, A., Dannull, J., Eruslanov, E., Kübler, H., Yancey, D., Dahm, P. & Vieweg, J. (2008) Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clinical Cancer Research, 14, 8270-8278.
27. Le, H.K., Graham, L., Cha, E., Morales, J.K., Manjili, M.H. & Bear, H.D. (2009) Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. International Immunopharmacology, 9, 900-909.
28. Lin, Y., Gustafson, M.P., Bulur, P.A., Gastineau, D.A., Witzig, T.E. & Dietz, A.B. (2011) Immunosuppressive CD14+HLA-DRlow/neg monocytes in B-cell non-Hodgkin's lymphoma. Blood, 117, 872-881.
29. Liu, Y., Zeng, B., Zhang, Z., Zhang, Y. & Yang, R. (2008) B7-H1 on myeloid-derived suppressor cells in immune suppression by a mouse model of ovarian cancer. Clinical Immunology, 129, 471-481.
30. Liu, C.Y., Wang, Y.M., Wang, C.L., Feng, P.H., Ko, H.W., Liu, Y.H., Wu, Y.C., Chu, Y., Chung, F.T., Kuo, C.H., Lee, K.Y., Lin, S.M., Lin, H.C., Wang, C.H., Yu, C.T. & Kuo, H.P. (2009) Population alterations of L: -arginase- and inducible nitric oxide synthase-expressed CD11b(+)/CD14(-)/CD15(+)/CD33(+) myeloid-derived suppressor cells and CD8(+) T lymphocytes in patients with advanced-stage non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology, 136, 35-45.
31. Mandruzzato, S., Solito, S., Falisi, E., Francescato, S., Chiarion-Sileni, V., Mocellin, S., Zanon, A., Rossi, C.R., Nitti, D., Bronte, V. & Zanovello, P. (2009) IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. Journal of Immunology, 182, 6562-6568.
32. Marigo, I., Dolcetti, L., Serafini, P., Zanovello, P. & Bronte, V. (2008) Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunological Reviews, 222, 162-179.
33. Medina-Echeverz, J., Fioravanti, J., Zabala, M., Ardaiz, N., Prieto, J. & Berraondo, P. (2011) Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells. Journal of Immunology, 186, 807-815.
34. Mirza, N., Fishman, M., Fricke, I., Dunn, M., Neuger, A.M., Frost, T.J., Lush, R.M., Antonia, S. & Gabrilovich, D.I. (2006) All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Research, 66, 9299-9307.
35. Morales, J.K., Kmieciak, M., Knutson, K.L., Bear, H.D. & Manjili, M.H. (2009) GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells. Breast Cancer Research and Treatment, 123, 39-49.
36. Movahedi, K., Guilliams, M., Van den Bossche, J., Van den Bergh, R., Gysemans, C., Beschin, A., De Baetselier, P. & Van Ginderachter, J.A. (2008) Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood, 111, 4233-4244.
37. Munera, V., Popovic, P.J., Bryk, J., Pribis, J., Caba, D., Matta, B.M., Zenati, M. & Ochoa, J.B. (2010) Stat 6-dependent induction of myeloid derived suppressor cells after physical injury regulates nitric oxide response to endotoxin. Annals of Surgery, 251, 120-126.
38. Murdoch, C., Muthana, M., Coffelt, S.B. & Lewis, C.E. (2008) The role of myeloid cells in the promotion of tumour angiogenesis. Nature Reviews. Cancer, 8, 618-631.
39. Nagaraj, S. & Gabrilovich, D. (2007) Myeloid-derived suppressor cells. In: Immune-Mediated Diseases (eds by M.R. Shurin & Y.S. Smolkin), pp. 213-223. Springer, New York.
40. Nagaraj, S. & Gabrilovich, D.I. (2010) Myeloid-derived suppressor cells in human cancer. Cancer Journal, 16, 348-353.
41. Nagaraj, S., Youn, J.-I., Weber, H., Iclozan, C., Lu, L., Cotter, M.J., Meyer, C., Becerra, C.R., Fishman, M., Antonia, S., Sporn, M.B., Liby, K.T., Rawal, B., Lee, J.-H. & Gabrilovich, D.I. (2010) Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clinical Cancer Research, 16, 1812-1823.
42. Nefedova, Y., Cheng, P., Gilkes, D., Blaskovich, M., Beg, A.A., Sebti, S.M. & Gabrilovich, D.I. (2005) Activation of dendritic cells via inhibition of Jak2/STAT3 signaling. Journal of Immunology, 175, 4338-4346.
43. Nefedova, Y., Fishman, M., Sherman, S., Wang, X., Beg, A.A. & Gabrilovich, D.I. (2007) Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Research, 67, 11021-11028.
44. Nizar, S., Copier, J., Meyer, B., Bodman-Smith, M., Galustian, C., Kumar, D. & Dalgleish, A. (2009) T-regulatory cell modulation: the future of cancer immunotherapy? British Journal of Cancer, 100, 1697-1703.
45. Ostrand-Rosenberg, S. (2010) Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunology, Immunotherapy, 59, 1593-1600.
46. Parrinello, N., La Cava, P., Tibullo, D., Giallongo, C., Di Bartolo, O., Spina, E., Cavalli, M., Schinocca, L., Triolo, A., Romano, A., Chiarenza, A., Palumbo, G.A. & Di Raimondo, F. (2009a) Myeloid-derived suppressor cells in patients with multiple myeloma and monoclonal gammopathy of undetermined significance. Blood (ASH Annual Meeting Abstracts), 114, abstract 4890.
47. Parrinello, N., La Cava, P., Tibullo, D., Giallongo, C., Di Bartolo, O., Spina, P., Fiumara, P., Schinocca, L., Conticello, C., Chiarenza, A., Palumbo, G.A. & Di Raimondo, F. (2009b) Myeloid-derived suppressor cells in patients with hodgkin lymphoma. Blood (ASH Annual Meeting Abstracts), 114, abstract 3662.
48. Poschke, I., Mougiakakos, D., Hansson, J., Masucci, G.V. & Kiessling, R. (2010) Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Research, 70, 4335-4345.
49. Ribechini, E., Leenen, P.J. & Lutz, M.B. (2009) Gr-1 antibody induces STAT signaling, macrophage marker expression and abrogation of myeloid-derived suppressor cell activity in BM cells. European Journal of Immunology, 39, 3538-3551.
50. Rodrigues, J.C., Gonzalez, G.C., Zhang, L., Ibrahim, G., Kelly, J.J., Gustafson, M.P., Lin, Y., Dietz, A.B., Forsyth, P.A., Yong, V.W. & Parney, I.F. (2010) Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro-Oncology, 12, 351-365.
51. Rodriguez, P.C., Quiceno, D.G., Zabaleta, J., Ortiz, B., Zea, A.H., Piazuelo, M.B., Delgado, A., Correa, P., Brayer, J., Sotomayor, E.M., Antonia, S., Ochoa, J.B. & Ochoa, A.C. (2004) Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Research, 64, 5839-5849.
52. Rodriguez, P.C., Ernstoff, M.S., Hernandez, C., Atkins, M., Zabaleta, J., Sierra, R. & Ochoa, A.C. (2009) Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Research, 69, 1553-1560.
53. Serafini, P., Borrello, I. & Bronte, V. (2006a) Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Seminars in Cancer Biology, 16, 53-65.
54. Serafini, P., Meckel, K., Kelso, M., Noonan, K., Califano, J., Koch, W., Dolcetti, L., Bronte, V. & Borrello, I. (2006b) Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. Journal of Experimental Medicine, 203, 2691-2702.
55. Serafini, P., Mgebroff, S., Noonan, K. & Borrello, I. (2008) Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Research, 68, 5439-5449.
56. Shaked, Y. & Voest, E.E. (2009) Bone marrow derived cells in tumor angiogenesis and growth: are they the good, the bad or the evil? Biochimica et Biophysica Acta, 1796, 1-4.
57. Sinha, P., Okoro, C., Foell, D., Freeze, H.H., Ostrand-Rosenberg, S. & Srikrishna, G. (2008) Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. Journal of Immunology, 181, 4666-4675.
58. Srivastava, M.K., Sinha, P., Clements, V.K., Rodriguez, P. & Ostrand-Rosenberg, S. (2010) Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Research, 70, 68-77.
59. Ugel, S., Delpozzo, F., Desantis, G., Papalini, F., Simonato, F., Sonda, N., Zilio, S. & Bronte, V. (2009) Therapeutic targeting of myeloid-derived suppressor cells. Current Opinion of Pharmacology, 9, 470-481.
60. Van Valckenborgh, E., Van Ginderachter, J., Movahedi, K., Menu, E. & Vanderkerken, K. (2009) Myeloid-derived suppressor cells in multiple myeloma. Blood (ASH Annual Meeting Abstracts), 114, abstract 2794.
61. Veltman, J., Lambers, M., van Nimwegen, M., Hendriks, R., Hoogsteden, H., Aerts, J. & Hegmans, J. (2010) COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. BioMed Central Cancer, 10, 464.
62. Vincent, J., Mignot, G., Chalmin, F., Ladoire, S., Bruchard, M., Chevriaux, A., Martin, F., Apetoh, L., Rebe, C. & Ghiringhelli, F. (2010) 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Research, 70, 3052-3061.
63. Vuk-Pavlovic, S., Bulur, P.A., Lin, Y., Qin, R., Szumlanski, C.L., Zhao, X. & Dietz, A.B. (2010) Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer. Prostate, 70, 443-455.
64. Wei, S., Chen, X., Rocha, K., Qi, D., Tao, J., Gjertsen, N., Zhou, J., Liu, J., Gabrilovich, D., Epling-Burnette, P.K., Djeu, J.Y. & List, A.F. (2009) Myeloid-Derived Suppressor Cells (MDSC) Are effectors of bone marrow suppression in lower risk myelodysplastic syndromes (MDS). Blood (ASH Annual Meeting Abstracts), 114, abstract 597.
65. Wilcox, R.A., Nevala, W.K., Thompson, M.A., Witzig, T.E., Ansell, S.M. & Markovic, S.N. (2009) CD14+ hla-DR-/Lo Myeloid-derived suppressor cells express immunosuppressive B7-H family members and are depleted following taxane-based chemotherapy in melanoma. Blood (ASH Annual Meeting Abstracts), 114, abstract 464.
66. Xiang, X., Poliakov, A., Liu, C., Liu, Y., Deng, Z.B., Wang, J., Cheng, Z., Shah, S.V., Wang, G.J., Zhang, L., Grizzle, W.E., Mobley, J. & Zhang, H.G. (2009) Induction of myeloid-derived suppressor cells by tumor exosomes. Internation Journal of Cancer, 124, 2621-2633.
67. Youn, J.-I. & Gabrilovich, D.I. (2010) The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. European Journal of Immunology, 40, 2969-2975.
68. Youn, J.-I., Nagaraj, S., Collazo, M. & Gabrilovich, D.I. (2008) Subsets of myeloid-derived suppressor cells in tumor-bearing mice. Journal of Immunology, 181, 5791-5802.
69. Zabaleta, J., McGee, D.J., Zea, A.H., Hernandez, C.P., Rodriguez, P.C., Sierra, R.A., Correa, P. & Ochoa, A.C. (2004) Helicobacter pylori arginase inhibits T cell proliferation and reduces the expression of the TCR zeta-chain (CD3zeta). Journal of Immunology, 173, 586-593.
70. Zea, A.H., Rodriguez, P.C., Atkins, M.B., Hernandez, C., Signoretti, S., Zabaleta, J., McDermott, D., Quiceno, D., Youmans, A., O'Neill, A., Mier, J. & Ochoa, A.C. (2005) Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Research, 65, 3044-3048.